ArticleHealth science reports2026
Stroke Reduction Therapies, Shared Decision-Making, and Patient Decision Aids: An Opportunity for Improved Quality and Inclusion in the Management of Atrial Fibrillation-A Perspective Piece.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is associated with 20% of the ischemic strokes in the United States. Atrial fibrillation related ischemic strokes can be reduced by pharmacologic and non-pharmacologic therapies. The decision-making process for selecting stroke reduction therapies is complex and should be individualized based on patient preferences and values, the risk and benefits of treatment, and the impact on the quality of life. Shared decision-making (SDM) operationalized through patient decision aids (PDAs) provides an opportunity to improve the decision-making process for stroke reduction therapies used in AF. Unfortunately, a limited number of PDAs for stroke reduction therapies in AF exist. Furthermore, it is unclear whether these aids were created in an evidence-based fashion and tailored to specific populations. Key Arguments: This perspective advocates for future amendments to the International Patient Decision Aids Standards (IPDAS) and the National Standards for the Certification of Patient Decision Aids that will facilitate the creation of evidenced based PDAs that move beyond a one-size fits all approach. Specifically, creation of diverse stakeholder advisory teams that utilize usability testing to create decision aids that are culturally responsive and perhaps tailored to vulnerable populations. Racial and ethnic minoritized populations with AF have the highest burden of poor outcomes. Black patients with AF had a twofold higher rate of stroke versus White patients (27.2 vs. 12.8 per 1000 per years) in the Atherosclerosis Risk in Communities Study. We hypothesize that SDM operationalized through PDAs has the chance to potentially reduce racial and ethnic disparities in the utilization of different stroke reduction therapies for AF. Conclusion: The process of SDM conducted via PDAs can improve the decision-making process for stroke reduction therapies in AF. Future studies should assess the feasibility of creating culturally tailored decision aids as well as their effectiveness in increasing the uptake of stroke reduction therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.